title: 21-day schedule oral etoposide in children--a feasibility study.
abstract: To determine the feasibility and toxicity of prolonged oral etoposide in children, 22 patients with relapsed or refractory disease were commenced on etoposide 50-100 mgs/m2 per day for 21 days. A second course was administered after full blood count recovery, followed by disease reassessment. In total, 72 courses were evaluable for toxicity, with 10% of completed courses complicated by febrile neutropenia. 15 patients were evaluable for response, with 1 partial response, 10 stable disease and 4 progressive disease. This schedule was well tolerated with acceptable toxicity when doses of less than 80 mg/m2/day were administered and warrants further evaluation.
authors.affiliation: Paediatric Unit, Royal Marsden Hospital, Sutton, Surrey, U.K.
authors.forename: A
authors.initials: A
authors.lastname: Davidson
authors.forename: I
authors.initials: I
authors.lastname: Lewis
authors.forename: A D
authors.initials: AD
authors.lastname: Pearson
authors.forename: M C
authors.initials: MC
authors.lastname: Stevens
authors.forename: C R
authors.initials: CR
authors.lastname: Pinkerton
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D009447:Neuroblastoma / Q000188:drug therapy; D009503:Neutropenia / Q000139:chemically induced; D012509:Sarcoma / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome
chemical_list: D005047:Etoposide